Additionally, insights into the tumor microenvironment and validation of key genes like STAT1 open avenues for development of targeted therapies, immunotherapies, and potential biomarkers to guide clinical decision-making in cutaneous melanoma management. The gene discussed is STAT1; the disease is cutaneous melanoma.